The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

AbbVie is investing $195m to strengthen domestic active pharmaceutical ingredient (API) production within the US, with the ...

AbbVie will invest $195M to expand API manufacturing at its North Chicago plant, boosting U.S. pharmaceutical innovation, ...

The global biopharma firm will build a new API production facility near its global headquarters in North Chicago.

Drugmaker AbbVie plans to construct a $195 million facility near its headquarters in North Chicago to manufacture active pharmaceutical ingredients, The Chicago Tribune reported Aug. 12. Construction ...

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

US pharma major AbbVie yesterday announced a $195 million investment in its North Chicago, Illinois manufacturing plant to ...

Steve Grzanich has the business news of the day with the Wintrust Business Minute. Abbott Laboratories spinoff AbbVie will ...

The company’s commitment to its North Chicago, Ill. plant is part of a previously announced $10 billion capital investment ...

AbbVie (NYSE: ABBV) has unveiled a $195 million investment to expand its North Chicago manufacturing plant to include domestic active pharmaceutical ingredient (API) production. The expansion is part ...

Insmed received FDA clearance for the first treatment for a chronic lung disease, opening the way to what could be a ...

The new North Chicago facility, slated to open in 2027, will boost domestic production of key drug ingredients for immunology ...